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Abstract
Deleted in Liver Cancer 1 (DLC1) is a RhoGAP-containing tumor suppressor that associates with 
various types of cancer. Although DLC2 shares a similar domain structure with that of DLC1, the 
function of DLC2 is not well characterized. Here, we describe the expression and ablation of 
DLC2 in mice using a reporter-knockout approach. DLC2 is expressed in several tissues and in 
endothelial cells (ECs) of blood vessels. Although ECs and blood vessels show no histological 
abnormalities and mice appear overall healthy, DLC2 mutant mice display enhanced angiogenic 
responses induced by matrigel and by tumor cells. Silencing of DLC2 in human ECs has reduced 
cell attachment, increased migration, and tube formation. These changes are rescued by silencing 
of RhoA, suggesting that the process is RhoA pathway dependent. These results indicate that 
DLC2 is not required for mouse development and normal vessel formation, but may protect mouse 
from unwanted angiogenesis induced by for example tumor cells.
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Introduction
Deleted in liver cancer (DLC) is a group of three genes that are highly related to each other 
based on their amino acid sequences (Liao & Lo, 2008). They all contain the SAM (sterile 
alpha motif), RhoGAP (RhoGTPase activation protein), and START (steroidogenic acute 
regulatory (StAR)-related lipid transfer) domains, and localize to focal adhesion sites. DLC1 
was isolated as a candidate tumor suppressor for liver cancer (Yuan et al., 1998). Further 
studies have detected down-regulation of DLC1 in various types of cancers. Genomic 
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deletion and promoter hypermethylation are two main causes of DLC1 down-regulation in 
cancer patients (Durkin et al., 2007b). Mutations that lead to early translational termination 
and functional alteration of DLC1 protein have also been identified (Liao et al., 2008). 
DLC1 is known to regulate cell shape, attachment, migration, proliferation and cell survival 
(Durkin et al., 2007b; Liao & Lo, 2008). Re-expression of DLC1 in DLC1 null cancer cell 
lines efficiently suppresses cancer cell growth. The tumor cell suppression activity is highly 
reliant on DLC1's RhoGAP domain and focal adhesion localization (Liao et al., 2007; Qian 
et al., 2007). These findings strongly suggest that DLC1 is a bona fide tumor suppressor.
DLC2 (also called STARD13) protein shares the same domain structure with DLC1. It is 
also under-expressed in some types of cancer and suppresses tumor cell growth by inhibition 
of RhoA activity through its RhoGAP domain (Ching et al., 2003; Leung et al., 2005; 
Ullmannova & Popescu, 2006). Significant correlations between under-expression of DLC2 
and cell differentiation as well as overexpression of RhoA in hepatocellular carcinoma have 
been reported (Xiaorong et al., 2008). Patients with DLC2-negative expression showed a 
significantly poorer prognosis than those with DLC2-positve hepatocellular carcinoma 
(Xiaorong et al., 2008). However, the overall expression pattern of DLC2 and its in vivo 
function are largely unknown.
In this report, we describe the expression pattern of DLC2, the effect of DLC2 deletion in 
mice, the role of DLC2 in endothelial cells, and its function in angiogenesis.
Results
Generation of DLC2 reporter knockout mice
To investigate the in vivo function of DLC2, we generated DLC2 knockout (KO) mice by 
using a DLC2 targeted ES cell clone from the Knockout Mouse Project Repository. The 
targeting vector was constructed (figure 1A) using the promoterless targeting cassette with 
the En2 splice acceptor/β-galactosidase/Neo/Poly-A sequences flanked by two FRT sites 
followed by the mouse DLC2 exon 3 flanked by two loxP sites for the generation of a 
“knockout-first allele” (Testa et al., 2004). The engineered β-galactosidase is expressed only 
under the endogenous DLC2 promoter and simultaneously disrupts the expression of DLC2. 
This targeting strategy allows us to produce reporter knockouts, and if necessary conditional 
knockouts and null alleles by exposure to site-specific recombinases Cre and Flp. Only 
reporter knockouts are described in this report. The mouse genotypes were determined by 
PCR assay (figure 1B). To confirm the lack of DLC2 protein expression, tissue lysates from 
wild type (WT) and homozygous mice were immunoprecipitated and immunoblotted with 
anti-DLC2 or anti-β-galactosidase antibodies (figure 1C). The lack of DLC2 in the 
homozygous lung, liver, kidney and heart demonstrated the interruption of DLC2 expression 
in the mutant mice. The presence of β-galactosidase in the KO tissue samples further 
confirmed the replacement of DLC2 by the reporter.
DLC2 overall expression pattern in a mouse
Although we have developed antibodies against DLC2 suitable for immunoprecipitation and 
immunoblot assays (figure 1C), the antibodies do not appear to detect DLC2 by 
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immunohistochemistry (IHC) staining. In order to analyze DLC2 expression pattern, we 
utilized the reporter system of DLC2 mutant mice with X-gal staining (figure 2A). Very 
intense X-gal blue staining was detected in alveolar epithelial cells of lung, hepatocytes of 
liver, cardiac myocytes in heart, and ependymal cells of brain. In stomach, the stained cells 
were found in muscularis, lamina propria, but not in epithelium. In kidney, the staining was 
strong in renal tubules of papilla and medulla regions, but was dispersed in the cortex area 
except the medullary ray. In testis, the stained cells were in the center of the seminiferous 
tubule while the peripheral cells had no staining. In ovary, staining was observed in oocytes. 
No staining in granulose cells of follicles but strong staining in all the granular lutein cells of 
corpus luteum was detected (not shown). Staining was also observed in islets in pancreas, 
epithelium of prostate, pigmented epithelium and ciliary processed of the eye. Although 
there was X-gal positive staining in thymus, spleen, skeletal muscle, small intestine, colon, 
and other tissues, the staining patterns were similar to the blood vessels. To confirm this, 
umbilical vessels, stomach, and skeletal muscle were sectioned for CD31 (a surface marker 
for endothelial cells) and X-gal staining (figure 2B). The results demonstrated that the X-gal 
staining was highly concentrated at endothelial cells. Tissue samples shown in figure 2 were 
from DLC2 homozygous mice. Nonetheless, DLC2 heterozygous mice display the same X-
gal staining pattern (not shown).
Loss of DLC2 promotes angiogenesis
Despite DLC2 being expressed in various tissues, we failed to observe histological 
abnormality in DLC2 KO mice (as shown in figure 2) and mice appeared normal and 
healthy, indicating that DLC2 is not required for embryo development and mouse survival. 
In addition, the microvascular density and morphology in stomach, skeletal muscle, brain 
were examined and and no difference between WT and KO mice was detected (figure 2; 
data not shown). The fact that DLC2 is highly concentrated in endothelial cells but does not 
produce an overt phenotype in mice has prompted us to challenge these mice with matrigel 
to assess the role of DLC2 during angiogenesis. Matrigel (growth factors reduced) was 
injected subcutaneously into WT and KO mice to induce neovascularization and formed 
matrigel plugs were removed and analyzed 4 day later. The matrigel plugs from the KO 
mice appeared bloodier and had a higher hemoglobin concentration than the WT (figure 
3A). IHC staining also confirmed a significantly higher population of CD31 positive cells in 
plugs from KO. To further examine DLC2's function in vessel formation, mouse aorta 
sections were grown in a 3D matrigel culture to observe EC sprouting. Consistent with in 
vivo matrigel plug results, we detected significantly increased ex vivo sprouting in DLC2 
KO samples (figure 3B). These data suggest that DLC2 may modulate angiogenic responses 
of endothelial cells.
Lack of DLC2 enhances angiogenesis induced by tumor cells but not by wound
As loss of DLC2 promotes angiogenesis in Matrigel plug assay, we further analyzed 
angiogenesis induced by wound in WT mice and DLC2 KO mice. The rate of skin wound 
healing showed no apparent difference between these two groups of mice. The vascular 
density was evaluated by CD31 IHC staining 7 days after wound in order to quantify 
wound-induced angiogenesis. The result showed similar microvascular densities in the 
granulation tissues of DLC2 KO mice compared to the WT mice (figure 4A). We further 
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analyzed whether loss of DLC2 could promote angiogenesis induced by tumor cells. B16 
murine melanoma tumor cells were implanted into the dorsal skin of WT and DLC2 KO 
mice. After 11 days, the mean size of tumors implanted in DLC2 KO mice was significantly 
larger than that in WT mice (figure 4B). In addition, the microvascular densities in tumors 
were significantly higher in KO than WT mice (figure 4B).
DLC2 regulates endothelial cell attachment and migration through a RhoA dependent 
pathway
To analyze the role of DLC2 in endothelial cells and the molecular mechanism involved, we 
have applied the siRNA approach. Silencing of DLC2 in HUVECs (human umbilical vein 
endothelial cells) significantly reduced cell attachment and promoted cell migration (figure 
5). In addition, down-regulation of DLC2 also enhanced tube formation of HUVEC on 
matrigel. These in vitro results are consistent with our in vivo findinsg and support the idea 
that DLC2 negatively regulates angiogenesis by modulating endothelial cell attachment and 
migration.
Since many of DLC1's function is dependent on its RhoGAP activity, we examined whether 
the observed phenotypes in DLC2 knockdown HUVECs could be rescued by interrupting 
RhoA, the main target of DLC's RhoGAP. As shown in figure 5, treatment of siRNA against 
RhoA in the DLC2 knockdown HUVECs reversed the phenotypes in cell attachment, 
migration, and tube formation back to levels similar to those of control HUVECs, suggesting 
that DLC2 regulated these cellular processes through a RhoA dependent matter.
Discussion
By using the reporter-knockout approach, we have established the expression pattern of 
DLC2. Overall, DLC2 expression pattern is very similar to those of DLC1 and DLC3 
(Durkin et al., 2007a; Durkin et al., 2002), although the levels are variable in some tissues. 
The similar expression patterns may explain the lack of developmental defects in DLC2 
mutant mice due to compensation and/or functional redundancy. Our findings are overall in 
agreement with the recent report by Ng's group (Yau et al., 2009) that DLC2 is not required 
for mouse development and survival. However, although they reported that their DLC2-
deficient mice were smaller and had less adipose tissue than the WT mice, we did not detect 
any difference in mouse body weight nor epididymal fat pad weight in our DLC2 KO mice 
(data not shown). In contrast to DLC2, lack of DLC1 leads to embryonic lethality with 
defects in the neural tube, brain, heart, and placenta (Durkin et al., 2005), indicating that 
DLC1 is not replaceable in embryogenesis. It will be interesting to investigate DLC3 
knockout mice and double knockout among DLC family members to sort out their common 
and unique functions.
It is intriguing that matrigel was able to induce stronger angiogenesis in the DLC2 KO mice. 
Apparently, DLC2 KO endothelial cells were more sensitive to certain components within 
the matrigel, which is a solubilized basement membrane preparation extracted from the 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma. The major components are laminin, 
collagen IV, heparin sulfate proteoglycan, and nidogen. In addition, trace amounts of TGFb 
(1.7 ng/ml), IGF-1 (5 ng/ml), EGF (0.5 ng/ml), NGF (<0.2 ng/ml), PDGF (<5 pg/ml), and 
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bFGF (<0.1 pg/ml) were detected in the growth factors reduced version of martigel used in 
this study. Whether DLC2 KO endothelial cells are more sensitive to one or more of these 
factors or other unknown factors in the matrigel warrants further investigation. Consistent 
with the matrigel plug results, our B16 tumor cell xenograft studies also demonstrated that 
DLC2 KO endothelial cells responded better to factors produced by tumor cells than the WT 
cells did.
Reduced expression of DLC2 in breast, liver, lung, renal, colon, ovarian, uterine, and gastric 
cancers has been reported. In vitro data suggest that DLC2 suppresses tumor cell 
proliferation and colony formation in a RhoGAP dependent fashion (Ching et al., 2003; 
Leung et al., 2005). Together with its sequence homology to DLC1, DLC2 is proposed to 
function as a tumor suppressor. However, we did not observe spontaneous cancer 
development in DLC2 KO mice up to 20 months of age. Ng's group also showed that 
deficiency in DLC2 alone does not enhance hepatocarcinogenesis (Yau et al., 2009). It is 
very likely that it requires additional “hit(s)” for cancer formation. This is the case in DLC1, 
in which the lack of p53 and overexpression of c-myc in liver cells significantly promote 
tumor formation in the absence of DLC1 (Xue et al., 2008). It will be worthwhile to cross 
DLC2 KO mice with p53 null mice or other mouse cancer models to examine whether lack 
of DLC2 will enhance tumor progression in these mice. These studies are especially 
important since we have demonstrated a novel function of DLC2 in angiogenesis, which is 
an important process in growth and development, as well as in pathological processes. 
Tumor Angiogenesis is required for the non-invasive tumor to grow and for advanced tumor 
to spread (metastasis). In our case, dysregulated DLC2 is not directly associated with tumor 
cell proliferation, but allows endothelial cells responding more sensitive to certain factors 
released by tumor cells. Our B16 xenograft results demonstrated that loss of DLC2 enhances 
tumor angiogenesis and accelerates tumor development. Although the overall incidence of 
diethylnitrosamine-induced hepatocarcinogenesis was not increased in 35 weeks old DLC2 
KO mice (Yau et al., 2009), it is possible that the effect of DLC2 deficiency is only critical 
at the early stage. It might be worthwhile to examine the diethylnitrosamine-treated mice at 
earlier time points. Interestingly, loss of DLC2 does not promote wound-induced 
angiogenesis in skin, indicating that DLC2 is not involved in all kinds of angiogenesis. In 
addition to cancer, angiogenesis also occurs in diabetic blindness, psoriasis, and rheumatoid 
arthritis. Whether DLC2 is participated in these diseases remains to be studied. Our studies 
suggest that the DLC2 KO mouse line may be a unique mouse model for disease-related 
angiogenesis studies.
Materials and Methods
Generation of DLC2 mice and genotyping
A DLC2 targeted ES cell clone was obtained from the Knockout Mouse Project Repository 
and injected into C57BL/6 blastocysts. The resulting male chimeras were mated with 
BALB/c females, and the DLC2 line was subsequently maintained on a C57BL/6 genetic 
background for five generations. Genotyping was performed by polymerase chain reaction 
(PCR) assay with primers specific for mouse DLC2 (a: F- ccaccccagttggcatgagtc and b: R- 
tacaactactctgcgaagtgc) and en2-β-geo (c: R- ccaactgaccttgggcaagaacat) to amplify a 1340-bp 
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fragment from the WT allele or a 351-bp fragment from the targeted allele. The PCR was 
performed at 94 °C for 5 min and followed by 30 cycles at 94 °C for 30s, 65 °C for 30s and 
72 °C for 70s, 1 cycle at 72 °C for 7 min.
X-Gal staining
Mouse tissues were fixed in fixation buffer (0.2% glutaraldehyde in PBS plus 2 mM MgCl2, 
5 mM EGTA, and 0.02% NP-40, pH 7.3) at 4 °C for 4 h and embedded in OCT compound 
(Sakura). Frozen sections (10 μm) were re-fixed in fixation buffer at 4 °C for 10 min and 
washed three times in washing buffer (PBS plus 2 mM MgCl2, 5 mM EGTA, 0.02% NP-40, 
and 0.01% Na-deoxycholate, pH 7.3) and stained at 37 °C for 6 h in the washing buffer with 
1 mg/ml X-gal, 5 mM potassium ferricyanide, and 5 mM potassium ferrocyanide, and 
counterstained with nuclear fast red.
Immunohistochemistry
Frozen sections were fixed in cold acetone for 10 min. Endogenous peroxidase activity was 
blocked in 3% hydrogen peroxide in methanol for 30 min. Slides were incubated at 4 °C 
overnight with rat anti-mouse CD31 (Pharmingen, San Jose, CA) at 1:200 dilution. Signal 
was detected with Vectastain ABC Elite Kit (Vector Laboratories, Burlingame, CA) and 
developed with diaminobenzidine substrate. Slides were counterstained with hematoxylin.
Matrigel plug assay
Growth factor-reduced matrigel (250 μl, BD Biosciences, San Jose, CA) containing 60 U/ml 
heparin (Sigma-Aldrich, St. Louis, MO) was subcutaneously injected into the mice (4–6 
weeks old). After 4 days, matrigel plugs were harvested, photographed, and hemoglobin 
content was measured with Drabkin reagent (Ricca Chemical, Arlington, TX). Plugs were 
embedded in OCT and frozen sections were processed for immunohistochemical staining 
using CD31 antibody.
Mouse aortic ring assay
The mouse aortic ring assay was performed as described by Masson et al (Masson et al., 
2005). Thoracic aortas were dissected and transferred to ice-cold DMEM. The fibroadipose 
tissus were removed and 1 mm long aortic rings were sectioned and embedded in growth 
factor-reduced matrigel within prepared cylindrical agarose wells. The aortic rings were 
cultured for two weeks and the outgrowth of endothelial tubes was counted.
Skin wound healing assay
Mice (12-week-old) were anesthetized and the surgical procedure was performed under 
aseptic conditions. Four full-thickness wounds were made on the backs of mice using a 2-
mm skin punch (Acudern, Fort Lauderdale, FL). Seven days later, mice were euthanized and 
wounds were excised and embedded in OCT and frozen sections were processed for 
immunohistochemical staining using CD31 antibody as previously described. Photographs 
were taken and CD31 positive microvascular density were determined by Photoshop 7.0 
(Adobe systems In., San Jose, CA) and ImageJ software (NIH).
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B16 murine melanoma tumor cells were injected (3 × 106 cells in 100 μl of PBS) 
subcutaneously into the DLC2 KO and WT mice (4–6 weeks old). After 11days, mice were 
sacrificed. Tumors were dissected, weighed and embedded. Microvascular density was 
assessed.
Wound healing migration assay
HUVECs were seeded on 6-well plates and cultured to confluence. The confluent monolayer 
was wounded with yellow tips and was allowed to migration for 6 h. Photographs were 
taken and migration-distances were measured by ImageJ software (NIH).
Adhesion assay
HUVECs (1×104/well) were seeded on 96-well plates pre-coated with 5μg/ml human plasma 
fibronectin and allowed to adhere for 30 min. Non-attached cells were removed and attached 
cells were stained and counted.
In vitro angiogenesis assay
HUVECs were seeded on a thin layer of growth factor-reduced matrigel at 104 cells/well of 
a 96-well plate in full culture medium and allowed to form a tubular structure for 6 h. The 
samples were examined and photographed. The photos were processed using ImageJ 
software (NIH).
Transfection of siRNA
Short interfering RNA against the human DLC2 (5′CACCUUUCCAUCUCCUAAUTT), 
RhoA (GGCAGAGAUAUGGCAAACATT), and the universal negative control siRNA 
were used. The siRNAs were transfected into HUVECs by using Lipofectamine2000 
(Invitrogen, Carlsbad, CA) per the manufacturer's protocol.
Antibody Production
Anti-DLC2 rabbit serum was raised against GST-DLC2 (154–395 aa) fusion protein. Anti-
DLC2 antibodies were purified by affinity matrix using recombinant DLC2 (154–395aa) 
protein without the GST portion.
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Figure 1. Generation of DLC2 reporter knockout mice
(A) Schematic diagram of targeting vector. (B) A representative genotyping by PCR 
analysis using primers specific for mouse DLC2 (a & b) and en2-β-geo (c). (C) Lung, liver, 
kidney and heart tissue lysates from wild-type (+/+) and homozygous (−/−) DLC2 mice 
were immunoprecipitated and immunoblotted with anti-DLC2 or anti-β-galactosidase to 
show that DLC2 protein expression was replaced by β-galactosidase in KO mice. Note that 
DLC2 is expressed at relatively low level in the wild-type kidney.
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Figure 2. DLC2 expression pattern in mutant mice
(A) X-gal staining in 3-month-old DLC2 homozygous (−/−) mouse tissues. Arrows indicate 
blood vessels. Scale bar=50 μm. (B) X-gal and CD31 immunohistochemical staining in 
consecutive sections of umbilical vessel (upper panel), stomach vessels (lower panel, left) 
and skeletal muscle (lower panel, right) showed that DLC2 co-expressed at CD31-positive 
endothelial cell layer and that blood vessels were histologically normal in DLC2 mutant 
mice. Scale bar=50μm.
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Figure 3. Loss of DLC2 enhances angiogenic responses induced by matrigel
(A) Angiogenic responses to matrigel plugs were more robust in DLC2 KO compared with 
the WT. The matrigel plug was bloodier in KO (left panel). Plugs from KO showed 
significant higher total hemoglobin contents (right panel) and more CD31-positive 
endothelial cells (lower panel) than WT samples. *p<0.05 (n=6). Scale bar=50μm. P-value 
was calculated by unpaired Student's t test. (B) Ex vivo sprouting of aortic explants from 
DLC2 KO is significantly enhanced. *p<0.05 (n=5). P-value was calculated by paired 
Student's t test.
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Figure 4. Lack of DLC2 enhances tumor development but not skin wound healing
(A) Skin wound healing tissue showed no difference in microvascular densities between the 
DLC2 KO and WT mice. P-value was calculated by unpaired Student's t test. P= 0.93 (n=8). 
Scale bar=50 μm. (B) Murine B16 tumor xenograft assays showed larger tumor sizes (upper 
panel) and higher microvascular densities (lower panel) in the DLC2 KO mice than WT 
mice. P-values were calculated by unpaired Student's t test. *p<0.05 (n=6). Scale bar=50 
μm.
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Figure 5. DLC2 regulates HUVEC attachment, migration, and tube formation in a RhoA 
dependent matter
HUVECs transfected with indicated siRNAs were used for immunoblotting analysis to 
confirm the knockdown efficiencies (A), cell attachment (B), wound healing migration (C), 
and in vitro angiogenesis assays (D). Representative images were shown. Each assay was 
independently performed three times. *p<0.05. P-values were calculated by unpaired 
Student's t test.
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